Ivan Borrello, MD
Enriched profileMedical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute · Tampa General Hospital Cancer Institute
Ivan Borrello is Medical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute at Tampa General Hospital Cancer Institute. OpenAlex indexes 282 publications with 21,949 citations (h-index 60); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Ivan Borrello, MD, is Medical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute at Tampa General Hospital Cancer Institute. The public record shows 282 publications with 21,949 citations (h-index 60), centered on Multiple Myeloma Research and Treatments, Immunotherapy and Immune Responses, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 33 companies.
- Most recent indexed publication: 2025 · Journal for immunotherapy of cancer
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 120.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 15 Oct 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202517 payments$36,598openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202512 payments$20,753openpaymentsdata.cms.gov ↗
- McKesson Sourcing Services, Inc.Program year202520 payments$12,407openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.7%Thalidomide Analog26.2%Lenalidomide63%Revlimid37%Part D<11 patientsBCL-2 Inhibitor5.9%Venclexta100%Part D<11 patients+ 1 more class in this area
Dermatology
21.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.5%Acyclovir100%Part D≥11 patientsAnti-infectives
12.2%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor7.6%Entecavir100%Part D<11 patientsShort-acting sulfonamides4.6%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
32 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Implementation of an innovative hospital at home program for patients with hematalogic malignancies
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Tumor-specific CD8(+) T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes.
Journal for immunotherapy of cancer
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ivan-borrello-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ivan-borrello-912bab7
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Ivan-Borrello-3
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/myeloma-crowd-radio-ivan-borrello-md-johns-hopkins/id683926347
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - Other
crunchbase.com/person/ivan-borrello
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →crunchbase.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile (listed as Associate Professor, Johns Hopkins University -- appears stale relative to current TGH role)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Doximity
Doximity physician profile (Oncology, Baltimore MD -- appears stale relative to current TGH/Tampa location)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Medical College of Virginia (Virginia Commonwealth University School of Medicine), Richmond
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org ↗ - Internal Medicine residency
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org ↗ - Medical Oncology fellowship
Johns Hopkins Oncology Center, Johns Hopkins University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org ↗
Editorial & leadership roles
journal and society appointments- Member
Hematologic Malignancies and Bone Marrow Translational Program / Cancer Immunology Working Group, American Association for Cancer Research (AACR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly Associate Professor of Oncology and Myeloma Program leader / Director of Cellular Therapies Core
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org ↗
Media & interviews
press, podcasts and appearances- OncLive contributor/interviewee
multiple video and written features on multiple myeloma treatment (e.g. "Dr. Borrello Sheds Light on the Multiple Myeloma Treatment Paradigm")
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens